导读:比利时鲁汶大学和鲁汶大学医院的Vander Poorten V, Meulemans J, Nuyts S等
在World J Surg Oncol(2015 Jul 16;13(1):214.)上报道题为“Postoperative photodynamic therapy as
a new adjuvant treatment after robot-assisted salvage surgery of recurrent squamous cell
carcinoma of the base of tongue”的文章,表示术后光动力治疗切除边缘残余病灶,随访显示
获得良好的肿瘤学和功能结果。
具体摘要信息如下:
BACKGROUND:背景
For patients who remain with involved resection margins after transoral robotassisted salvage surgery
(TORS) for recurrent squamous cell carcinoma (SCC) at the base of tongue (BOT) following primary
(chemo)radiotherapy, further adjuvant treatment options are very limited.
对于那些经口腔机器人手术进行边缘切除的复发性舌底鳞状细胞癌患者,后续进行放(化)疗治疗,
进一步的辅助治疗手段非常有限。
We want to report on our preliminary experience with a new adjuvant strategy using postoperative
temoporfin-mediated photodynamic therapy for this indication.
我们想要发表我们的初步经验,关于采用术后Temoporfin(替莫卟吩:一种光敏剂)-光动力治疗
该适应症的一项新的辅助治疗手段。
METHODS: 方法
Two patients with recurrent SCC after primary (chemo)radiotherapy of the BOT were treated with TORS,
but unfortunately remained with involved resection margins on the postoperative pathology report.
2例放(化)疗术后复发的舌底鳞状细胞癌患者接受了经口腔机器人手术,但是不幸的是术后病理报告
显示有切除边缘的浸润。
If left without additional treatment, these patients are prone to further recurrence. Temoporfin mediated photodynamic therapy
was used as a new adjuvant approach to treat the remaining microscopic disease at the resection margins.
如果放任而不进行进一步的治疗,这些病人之后很容易复发,Temoporfin(替莫卟吩:一种光敏剂)-
光动力疗法作为一项新的辅助治疗手段治疗切除边缘的遗留微小病灶。
RESULTS: 结果
Good oncological and functional results were obtained in these patients, now treated for a recurrence,
after a preceding full course of radiotherapy.
治疗4个疗程的放疗之后复发的肿瘤患者,这些病人获得了好的肿瘤学和功能结果。
Both are disease free at 42 and 24 months of follow-up and are able to speak, breathe, and eat normally.
2个病人分别随访42和24个月均无瘤生存,且可以正常的说话、呼吸和进食。
CONCLUSIONS: 结论
In selected patients that have undergone salvage surgery with positive resection margins, postoperative
temoporfin-mediated photodynamic therapy can result in a good oncological and functional outcome.
对于那些已经进行手术但切除边缘呈阳性的病人,术后 temoporfin(替莫卟吩:一种光敏剂)-光动力
治疗可以获得好的肿瘤学和功能结果。
文献来源信息:World J Surg Oncol. 2015 Jul 16;13(1):214
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503294/